Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis

doi:10.19803/j.1672-8629.20230140

Abstract

Abstract: Objective To establish the standard for evaluation of clinical use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis. Methods According to the National Pharmacopoeia of the People’s Republic of China (2020 edition), the Drug Catalogues for National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2021), the Guidelines for Clinical Application of Proprietary Chinese Medicine for Coronary Heart Disease (2020 edition) and the Guidelines for Clinical Application of Proprietary Chinese Medicine for Heart Failure (2021), all TCM injections for promoting blood circulation and removing blood stasis were sorted out. According to drug instructions, guidelines and clinical use, the indicators for evaluation were identified, and the standard for evaluation was established using the Delphi method. Data on TCM injections for promoting blood circulation and removing blood stasis used in the Department of Cardiology between January 1 and June 30, 2022 was collected. The Technique for Order Preference by Similarity to an Ideal Solution was used for evaluation. Results A total of 21 indications of TCM injections for promoting blood circulation and removing blood stasis were included before primary and secondary evaluation indexes were established in terms of indications, solvents, usage and dosage, excipients, compatibility and special populations. According to the results of evaluation, 107 patients (89.17%) with Ci≥60% were identified from among 120 patients receiving TCM injections for promoting blood circulation and removing blood stasis, indicating that the usage of these TCM injections in the Department of Cardiology was generally proper. Conclusion The establishment of a standard for evaluation can help improve the rationality of the way in which TCM injections for promoting blood circulation and removing blood stasis are used.

Key words: department of cardiology, promoting blood circulation and removing blood stasis, traditional Chinese medicine injection, drug instructions, standard for valuation, technique for order preference by similarity to an ideal solution

CLC Number:

R944
R994.11

ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230140

https://www.zgywjj.com/EN/Y2024/V21/I2/185

References

[1] NMPA. Annual report of national adverse drug reaction monitoring (2021[EB/OLJ]. (2022-03-30)[2022-04-26] . 2021)[EB/OLJ]. (2022-03-30)[2022-04-26] . http://www.nmpa.gov.cn/FGWJ-2021-131.
[2] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China,2020 Edition, Volume 1(中华人民共和国药典一部)[M] . Beijing: China Medical Science Press, 2020.
[3] National Healthcare Security Administration, Ministry of Human Resources and Social Security of the People’s Republic of China. On the publication of the drug catalogue of the state basic medical insurance, industrial injury insurance and maternity insurance (2021)(medical insurance issued〔2021〕No. 50)[EB/OL]. (2021-11-24)[2022-03-03].http://www.nhsa.gov.cn/art/2021/12/3/art_37_7429. html.
[4] MAO JY, WU YJ, SHI DZ.Guidelines for clinical application of Chinese patent medicines in the treatment of coronary heart disease (2020)[J]. Chinese Journal of Integrative Medicine on Cardio-cerebrovascular Disease(中西医结合心脑血管病杂志), 2021, 19(9): 1409-1435.
[5] MAO JY, ZHANG J, ZHU MJ.Clinical application guide of Chinese patent medicine in the treatment of heart failure (2021)[J]. Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志), 2022, 42(3): 261-275.
[6] WANG HP, CHEN GQ, QIU SS.Establishment and application of drug use evaluation criteria for apixaban[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2022, 31(11): 749-755.
[7] CHEN TD, GAO QL, REN JW, et al.Establishment of index system of accessibility to drugs for chronic diseases based on Delphi method[J]. Chin J Mod Appl Pharm(中国现代应用学),2022, 39(20): 2652-2657.
[8] YU HJ, LIU XM, GU YQ, et al.Construction of nursing quality index system about traditional Chinese medicine in cardiovascular patients based on Delphi method[J]. Journal of Nurses Training(护士进修杂志), 2022, 37(18): 1646-1650.
[9] WU CS, CHEN JX, HU LS.Duble percent method, the new method to determine the weight coefficient in building diagnostic criteria in TCM with Delpi method[J]. Chinese Journal of Basic Medicine in Traditional Chinese Medicine(中国中医基础医学杂志), 2006(4): 254-255.
[10] YANG WZ, HU ZH, XIE XF, et al.Evaluation on application rationality of antibiotics in patients with acute pancreatitis based on weighted TOPSIS method[J]. Evaluation and Analysis of Drug-use in Hospitals of China(中国医院用药评价与分析), 2021, 21(7): 853-857.
[11] RAN S, YU J, ZHU YL.Application of weighted TOPSIS to evaluate the use of voriconazole in one hospital[J]. Prac J Med＆Pharm(实用医药杂志), 2020, 37(7): 636-641.
[12] WANG GF, LIU RF, LIAO CX, et al.Application of weighted TOPSIS to evaluate the use of voriconazole in one hospital[J]. Evaluation and analysis of drug-use in hospitals of China(中国医院用药评价与分析), 2020, 20(12): 1672-2124.

[1]	LIU Jie, ZHANG Jianmin, ZHANG Xiaomeng, LIU Fang, SONG Yuan, ZHONG Xuli. Management of risks to pediatric medications based on drug instructions of Chinese patent medicines in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 422-427.
[2]	LI Shuran, GUO Shanshan, GAO Suangrong, BAO Lei, GENG Zihan, ZHAO Ronghua, ZHANG Jingsheng, PANG Bo, ZHANG Yu, WANG Yaxin, XU Yingli, CAO Shan, HAN Bing, CUI Xiaolan, SUN Jing. Effect of Lutongning granulethe to trigeminal neuralgia induced by chronic constriction injury of the infraorbital nerve in rats [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 257-262.
[3]	LIU Tiantian, CAO Junling, ZHANG Yanli, GONG Ying, GU Yuanyuan. Research progress in enhancing anticoagulant effects of warfarin and the mechanism by traditional Chinese medicine for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 117-120.
[4]	ZHANG Qingxia, JIANG Yongxian, DONG Yuexin, XIAN Ying, YAN Suying. Risk analysis and precautions related to storage conditions specified in package inserts of western medicines in a hospital [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 913-918.
[5]	ZHOU Peng, YANG Jingjing. Pharmaceutical care of three types of Qingrejiedu traditional Chinese medicine injections [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 441-445.
[6]	YI Yan, TIAN Jingzhuo, LI Chunying, ZHAO Yong, LIANG Aihua. Pesudoallergic reactions during post-marketing non-clinical safety reevaluation of traditional Chinese medicine injections [J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 185-188.
[7]	ZHAO Jianbin, HUANG Yuling. Risks and applications of parecoxib for injection based on drug instructions and judgment documents [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1250-1253.
[8]	WENG Lihong, GAO Huan, HU Xue, ZHANG Wenrui. Infusion Requirements on Labels of 39 Chinese Traditional Medicine Injections [J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 437-440.
[9]	LI Jian-ping, GUO Jian-ming, DUAN Jin-ao, FAN Xin-sheng, DU Xiao-xi, SUN Jun. Literature Study of Drug Combination Type and Incompatibility of Traditional Chinese Medicine Injections [J]. Chinese Journal of Pharmacovigilance, 2014, 11(7): 432-438.
[10]	LIU Han-qing, WANG Wen-gang, WANG Ai-ping. Immunotoxicity Evaluation Research Progression of Traditional Chinese Medicine Injections [J]. Chinese Journal of Pharmacovigilance, 2013, 10(7): 405-407.
[11]	LI Ji-you ,SUN Jun ,ZHOU Jing, HUANG Pei-qi . Analysis of Reduning Injection Related Risk Factors [J]. Chinese Journal of Pharmacovigilance, 2013, 10(10): 627-630.
[12]	SUN Qiu-ying, YE Zheng-liang, LIANG Yi. Introduction to TCMI Enterprises on How to Establish Risk Management System [J]. Chinese Journal of Pharmacovigilance, 2012, 9(2): 96-99.
[13]	BI Feng-lan, ZHANG Li. Discussion on the Safety of Traditional Chinese Medicine Injection [J]. Chinese Journal of Pharmacovigilance, 2012, 9(2): 89-91.
[14]	ZHANG Ying. Analysis of 97 Adverse Drug Reaction/Event Cases Induced by Traditional Chinese Medicine Injections [J]. Chinese Journal of Pharmacovigilance, 2011, 8(8): 498-500.
[15]	GAO Feng-li, AN Hui-yan. Investigate and Analysis of Adverse Drug Reaction of Seven Traditional Chinese Medicine Injections [J]. Chinese Journal of Pharmacovigilance, 2011, 8(5): 312-314.